Dynamics and control of the global tuberculosis epidemic

Current Opinion in Pulmonary Medicine

Volumn 6, Issue 3, 2000, Pages 174-179

  Bleed, D ^a   Dye, Chris ^a   Raviglione, M C ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION RISK; REVIEW; TUBERCULOSIS; WORLD HEALTH ORGANIZATION;

EID: 0033914031     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200005000-00002     Document Type: Review

References (42)

1. 1 World Health Report 1999: Making a Difference. Geneva: World Health Organization, 1999.
2. 2 Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC: Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. JAMA 1999, 282:677-686.
3. 3 King G: A Solution to the Ecological Inference Problem: Reconstructing Individual Behavior from Aggregate Data. Princeton University Press, 1997.
4. 4 Cantwell MF, McKenna MT, McCray E, Onorato IM: Tuberculosis and race/ethnicity in the United States: impact of socioeconomic status. Am J Respir Crit Care Med 1998, 157:1016-1020.
5. 5 Elender F, Bentham G, Langford I: Tuberculosis mortality in England and Wales during 1982-1992: its association with poverty, ethnicity and AIDS. Soc Sci Med 1998, 46:673-681.
6. 6 Williams A: Calculating the global burden of disease: time for a strategic reappraisal? Health Economics 1999, 8:1-8. A piercing critique of disease burden studies, though erring toward overstatement; one of a series of such commentaries that appeared during 1998-9.
7. 7 Wiseman V, Mooney G: Burden of illness estimates for priority setting: a debate revisited. Health Policy 1998, 43:243-251.
8. 8 Global Tuberculosis Control: WHO Report 1999. Geneva, World Health Organization, 1999.
9. 9 Ahmed Y, Mwaba P, Chintu C, Grange JM, Ustianowski A, Zumla A: A study of maternal mortality at the University Teaching Hospital, Lusaka, Zambia: the emergence of tuberculosis as a major non-obstetric cause of maternal death. Int J Tuberc Lung Dis 1999, 3:675-680.
10. 10 Pablos-Méndez A, Raviglione MC, Laszlo A, et al: Global surveillance for antituberculosis-drug resistance, 1994-1997. N Engl J Med 1998, 338:1641-1649. Until publication of the next report during 2000, this remains the most comprehensive study of the distribution of drug-resistant tuberculosis in the world.
11. 11 Anonymous: Primary multidrug-resistant tuberculosis: Ivanovo Oblast, Russia, 1999. Morb Mortal Wkly Rep 1999, 48:661-664.
12. 12 Coninx R, Mathieu C, Debacker M, et al: First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons. Lancet 1999, 353:969-973.
13. 13 Kimerling M, Kluge H, Vezhnina N, et al: Inadequacy of the current WHO re-treatment regimen in a central Siberian prison: treatment failure and MDR-TB. Int J Tuberc Lung Dis 1999, 3:451-453.
14. 14 Espinal M, Kim S, Hong Y, et al: Treatment outcome of multidrug resistant tuberculosis cases under programme conditions. Int J Tuberc Lung Dis 1998. 2:S371-S371.
15. 15 Farmer P, Kim JY: Community based approaches to the control of multidrug resistant tuberculosis: introducing DOTS-plus. Br Med J 1998, 317:671-674.
16. 16 Multidrug Resistant Tuberculosis (MDR TB): Basis for the Development of an Evidence-Based Case-Management Strategy for MDR TB within the WHO'S DOTS Strategy (Proceedings of 1998 Meetings and Protocol Recommendations). Espinal MA, ed. WHO/TB/99.260. Geneva: WHO, 1999.
17. 17 Espinal M, Dye C, Raviglione M, Kochi A: Rational 'DOTS Plus' for the control of MDR-TB. Int J Tuberc Lung Dis 1999, 3:561-563.
18. 18 Farmer P, Furin J, Bayona J, et al: Management of MDR-TB in resource-poor countries. Int J Tuberc Lung Dis 1999, 3:643-645.
19. 19 Program in Infectious Disease and Social Change. The Global Impact of Drug-Resistant Tuberculosis. Boston: Harvard Medical School, Open Society Institute, 1999.
20. 20 Heifets L, Cangelosi G: Drug susceptibility testing of mycobacterium tuberculosis: a neglected problem at the turn of the century. Int J Tuberc Lung Dis 1999, 3:564-581.
21. 21 Grosset J: Systematic drug susceptibility testing: a necessary component of the 'DOTS Plus' strategy? Int J Tuberc Lung Dis 1999, 3:549-550.
22. 22 Migliori G, Raviglione MC: Central and Eastern Europe. In: Clinical Tuberculosis, ed 2. Edited by Davies PD. London: Chapman & Hall Medical, 1998.
23. 23 EuroTB (CESES/KNCV) and the national coordinators for tuberculosis surveillance in the WHO European region: Surveillance of Tuberculosis in Europe: Report on Tuberculosis Cases Notified in 1997. Paris: EuroTB, 1999.
24. 24 Centers for Disease Control and Prevention: Reported tuberculosis in the United States, 1998. Atlanta: U.S. Department of Health and Human Services, 1999.
25. 25 MacIntyre CR, Plant AJ: Longitudinal incidence of tuberculosis in South-East Asian refugees after re-settlement. Int J Tuberc Lung Dis 1999, 3:287-293.
26. 26 Curtis A, Ridzon R, Vogel R, et al: Extensive transmission of mycobacterium tuberculosis from a child. N Engl J Med 1999, 341:1491-1495.
27. 27 Glynn JR, Vynnycky E, Fine PE: Influence of sampling on estimates of clustering and recent transmission of Mycobacterium tuberculosis derived from DNA fingerprinting techniques. Am J Epidemiol 1999, 149:366-371.
28. 28 Borgdorff MW, Veen J, Kalisvaart NA, Nagelkerke N: Mortality among tuberculosis patients in The Netherlands in the period 1993-1995. Eur Respir J 1998, 11:816-820. A study that combines the latest methods of laboratory and epidemiologic analysis to address an important public health question.
29. 29 Netto EM, Dye C, Raviglione MC: Progress in global tuberculosis control 1995-1996, with emphasis on 22 high-incidence countries. Int J Tuberc Lung Dis 1999, 3:310-320.
30. 30 Tuberculosis control: progress in 1995-1997. Weekly Epidemiological Record 1999, 74:217-227.
31. 31 Dye C, Garnett GP, Sleeman K, Williams BG: Prospects for worldwide tuberculosis control under the WHO DOTS strategy: directly observed short-course therapy. Lancet 1998, 352:1886-1891.
32. 32 Fine PE, Small PM: Exogenous reinfection in tuberculosis. N Engl J Med 1999, 341:1226-1227.
33. 33 Zwarenstein M, Schoeman J, Caesar V, Lombard C, Tatley M: Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet 1998, 352:1340-1343.
34. 34 Murray CJ, Salomon JA: Modelling the impact of global tuberculosis control strategies. Proc Natl Acad Sci U S A 1998, 95:13881-13886.
35. 35 Anderson R: Tuberculosis: Old problems and new approaches. Proc Natl Acad Sci U S A 1998, 95:13352-13354.
36. 36 Behr MA, Weerakiet S, Salamon H, et al: Transmission of mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet 1999, 353:444-449. An elegant reminder that transmission from sputum smear-negative patients is not trivial; a neat counterpoint to the DOTS focus on smear-positive disease.
37. 37 Vynnycky E, Fine PE: The long-term dynamics of tuberculosis and other diseases with long serial intervals: implications of and for changing reproduction numbers. Epidemiology of Infection 1998, 121:309-324.
38. 38 Vynnycky E, Fine PE: Interpreting the decline in tuberculosis: the role of secular trends in effective contact. Int J Epidemiol 1999, 28:327-334.
39. 39 Salpeter EE, Salpeter SR: Mathematical model for the epidemiology of tuberculosis, with estimates of the reproductive number and infection-delay function. Am J Epidemiol 1998, 147:398-406.
40. 40 van Rie A, Warren R, Richardson M, Victor TC: Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999, 341:1174-1179.
41. 41 Tuberculosis Research Centre (ICMR): Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Indian J Med Res 1999, 110:56-69.
42. 42 Pathania V, Trnka L, Krejbich F, Dye C: A cost-benefit analysis of BCG revaccination in the Czech Republic. Vaccine 1999, 17:1926-1935.